STAT - Reporting from the frontiers of health and medicine

STAT - Reporting from the frontiers of health and medicine

Lyme disease, when tested properly and caught early *can* be treated with a low-cost, effective dose of antibiotics. When Lyme bacteria lingers in the body untreated, the bacteria morph into stealthy spirochetes; the infection can then spread to the joints, the heart and the nervous system mimicking symptoms of Fibromyalgia, Chronic Fatigue Syndrome, MS, ALS, Parkinson’s and Alzheimer’s. (hence the nickname “the great imitator”). Neuropathy, carditis, arthritis are all common fallouts. This late-stage can cause incurable, irreversible conditions, which the doctors will only treat symptomatically with expensive, potentially harmful drugs such as gabapentin, Lyrica et al. All infectious disease doctors can do is shrug their shoulders and suggest supportive therapies and/or covert, integrative LLMD’s – neither of which are covered by insurance. (ask me how I know) CBD has already been FDA approved to treat seizures. Epidiolex runs an average annual cost of $32k – (hope you have comprehensive insurance). Wouldn’t it, therefore, make sense that if CBD can help alleviate epilepsy, it would work for other neuro conditions – FDA approved or not. Pharma would rather you spend your medical dollars at their bank than treating symptoms with a lower cost OTC solution. SD (Lyme & Babesia 2015; Chronic Lyme 2017)



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More